Eur J Intern Med. 2024;129:133-136.
Cardiovascular outcome with SGLT2i and GLP1RA.
제1저자 임수 · 교신저자 임수, Michael A Nauck
소속 (3)
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea. Electronic address: limsoo@snu.ac.kr.
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
- Section Diabetes, Endocrinology, Metabolism, Medical Department I Katholisches Klinikum Bochum gGmbH, St. Josef Hospital Ruhr-University Bochum, Bochum, Germany. Electronic address: michael.nauck@rub.de.
Keywords
Glucagon-like peptide 1Major adverse cardiac eventsMyocardial infarctionSodium-glucose transporter 2 inhibitorsStroke
Conflict of interest statement
Declaration of competing interest MAN has been a member of the advisory boards of, or has consulted with, Boehringer Ingelheim, Eli Lilly, Medtronic, Merck Sharp & Dohme, Novo Nordisk, Pfizer, Regor, Sun Pharma and Structure Therapeutics (ShouTi, Gasherbrum). He has received grant support from Merck Sharp & Dohme. He has also served on the speakers’ bureau of Eli Lilly, Menarini/Berlin Chemie, Merck Sharp & Dohme, Medscape, Medical Learning Institute and Novo Nordisk.
그 밖의 정보
- 출판 형태
- Letter
- 저널
- European journal of internal medicine · eISSN 1879-0828
- 전자 출판
- 2024-06-08